Menorrhalgia Market Report 2026

The menorrhalgia market size has grown strongly in recent years. It will grow from $21.91 billion in 2025 to $23.27 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high prevalence of hormonal imbalances, increased incidence of uterine fibroids and polyps, limited awareness of abnormal menstrual bleeding, widespread use of oral hormonal therapies, expansion of gynecology clinics.

The menorrhalgia market size is expected to see strong growth in the next few years. It will grow to $29.36 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing demand for fertility-preserving treatments, increasing adoption of long-acting intrauterine systems, rising focus on women’s reproductive health, expansion of access to gynecological care in emerging markets, growing acceptance of non-hormonal therapies. Major trends in the forecast period include rising preference for non-hormonal treatment options, growing awareness and early diagnosis of menorrhagia, increasing use of minimally invasive and intrauterine therapies, expansion of personalized gynecological treatment plans, higher focus on managing anemia and quality of life.

The increasing incidence of hormonal imbalances is expected to drive the growth of the menorrhalgia market in the coming years. Hormonal imbalances are disruptions in the body’s endocrine system in which hormone levels are either excessive or insufficient, leading to various health problems such as weight fluctuations, mood changes, fatigue, and reproductive issues. The growing prevalence of hormonal imbalances is attributed to lifestyle factors, environmental exposures, and underlying medical conditions. Contemporary lifestyles characterized by unhealthy diets, elevated stress levels, and insufficient physical activity interfere with normal hormone production and regulation. Hormonal imbalances can contribute to menorrhalgia (painful menstruation) by disturbing the normal regulation of the menstrual cycle and altering the uterine environment. For example, in January 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, polycystic ovary syndrome was identified as a major public health concern and one of the most common hormonal disorders among women of reproductive age, affecting an estimated 6-13% annually. Therefore, the rising prevalence of hormonal imbalances is fueling the growth of the menorrhagia market.

Rising obesity rates are anticipated to drive the expansion of the menorrhalgia market in the coming years. Obesity rates represent the share of the population with a body mass index (BMI) of 30 or above, reflecting excessive body fat that can negatively affect health. The growth in obesity rates is largely attributed to sedentary lifestyles, as reduced physical activity lowers calorie expenditure and promotes the accumulation of excess body fat. Management of menorrhagia can support obesity control by addressing hormonal imbalances and menstrual-related metabolic disturbances that often contribute to weight gain. For example, in May 2025, data from the Office for Health Improvement and Disparities, a UK-based government organization, indicated that between 2023 and 2024, approximately 64.5% of adults aged 18 years and older in England were overweight or living with obesity, an increase from 64% during 2022 to 2023. Consequently, the rise in obesity rates is fueling the growth of the menorrhagia market.

In January 2025, Hologic Inc., a US-based health technology company, acquired Gynesonics Inc. for an undisclosed sum. Through this acquisition, Hologic Inc. seeks to strengthen its range of minimally invasive treatments for uterine fibroids and heavy menstrual bleeding, thereby advancing women’s healthcare solutions. Gynesonics Inc. is a US-based medical device company that offers a system for the treatment of menorrhagia.

Major companies operating in the menorrhalgia market are AbbVie Inc., Bayer HealthCare Pharmaceuticals Inc., Boston Scientific Corporation, Johns Hopkins Health System Corporation, Aegea Medical Inc., Emory Healthcare Inc., Hologic Inc., Dr Reddys Laboratories Ltd., Meril Life Sciences Pvt Ltd, ASKA Pharmaceutical Holdings Co Ltd, Ferring Pharmaceuticals Group, Xanodyne Pharmaceuticals Inc., Pregna International Ltd., HLL Lifecare Limited, Actiza Pharmaceutical Pvt Ltd, Wellona Pharma, OCON Healthcare Ltd, Pfizer Inc., Medtronic plc, Myovant Sciences Ltd, Gedeon Richter Plc, Cooper Surgical Inc, Olympus Corporation, Takeda Pharmaceutical Company Limited, Novartis AG.

North America was the largest region in the menorrhalgia market in 2025. The regions covered in the menorrhalgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menorrhalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the menorrhalgia market by increasing costs associated with imported pharmaceutical ingredients, intrauterine devices, and specialty gynecological products. The impact is most evident in hormonal agents and long-acting intrauterine therapies, particularly in regions dependent on imported medications such as Asia-Pacific and Latin America. Higher input costs have influenced pricing across hospital and retail pharmacy channels. However, tariffs have also encouraged local manufacturing, generic drug development, and diversified sourcing strategies, supporting long-term treatment accessibility.

The menorrhalgia market research report is one of a series of new reports that provides menorrhalgia market statistics, including menorrhalgia industry global market size, regional shares, competitors with a menorrhalgia market share, detailed menorrhalgia market segments, market trends and opportunities, and any further data you may need to thrive in the menorrhalgia industry. This menorrhalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Menorrhalgia, also known as menorrhagia, is a condition marked by unusually heavy or extended menstrual bleeding. It involves menstrual cycles that continue for more than seven days or result in excessive blood loss, generally exceeding 80 milliliters per cycle. This condition can cause symptoms such as fatigue, anemia, and physical discomfort. Menorrhagia can arise from multiple causes, including hormonal imbalances, uterine fibroids, polyps, or other underlying medical conditions.

The primary categories of treatments for menorrhalgia include hormonal and non-hormonal therapies. Hormonal treatments help manage menorrhagia by regulating hormone levels to reduce uterine contractions, control the growth of the endometrial lining, and ease pain and bleeding. These medications can be delivered through several routes, such as oral, vaginal, transdermal, intrauterine, and other methods. They are made available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The menorrhalgia market consists of revenues earned by entities by providing services such as medical consultation, diagnostic testing, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The menorrhagia market also consists of sales of products including medications, medical devices, and supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.